A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

NCT05876832 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation

Interventions

DRUG: XY0206
DRUG: Salvage Chemotherapy

Sponsor

Shijiazhuang Yiling Pharmaceutical Co. Ltd